Tumor-associated calcium signal transducer 2 (TROP2), a clinically validated target in oncology, is a glycoprotein overexpressed in several solid tumors such as breast, lung, pancreatic, ovarian and prostate cancer. TROP2 antibody-drug conjugates (ADCs) have shown significant efficacy in a large number of cancer types but still are linked to substantial safety issues.